US 11,725,051 B2
Diagnosis and therapy of cancer involving cancer stem cells
Ugur Sahin, Mainz (DE); Ozlem Tureci, Mainz (DE); Korden Walter, Mainz (DE); Meike Wagner, Mainz (DE); Maria Kreuzberg, Mainz (DE); Sabine Hacker, Mainz (DE); and Stefan Jacobs, Mainz-Kastel (DE)
Assigned to BioNTech AG, Mainz (DE); Astellas Pharma Inc., Tokyo (JP); and TRON—Translationale Onkologie an der Universität, Mainz (DE)
Filed by BioNTech AG, Mainz (DE); Ganymed Pharmaceuticals GmbH, Mainz (DE); and TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz (DE)
Filed on Feb. 19, 2020, as Appl. No. 16/795,468.
Application 16/795,468 is a continuation of application No. 14/904,011, granted, now 10,604,568, previously published as PCT/EP2014/066330, filed on Jul. 30, 2014.
Claims priority of application No. PCT/EP2014/066330 (WO), filed on Jul. 30, 2014.
Prior Publication US 2020/0385460 A1, Dec. 10, 2020
Int. Cl. C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61K 31/337 (2006.01); A61K 31/5365 (2006.01); A61K 31/7048 (2006.01); A61K 31/7064 (2006.01); A61K 33/243 (2019.01); C07K 16/30 (2006.01); A61K 47/68 (2017.01); G01N 33/574 (2006.01); A61N 5/10 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/28 (2013.01) [A61K 31/337 (2013.01); A61K 31/5365 (2013.01); A61K 31/7048 (2013.01); A61K 31/7064 (2013.01); A61K 33/243 (2019.01); A61K 39/39558 (2013.01); A61K 47/6851 (2017.08); A61N 5/10 (2013.01); C07K 16/30 (2013.01); G01N 33/57484 (2013.01); G01N 33/57492 (2013.01); A61K 2039/505 (2013.01); C07K 2317/56 (2013.01); C07K 2317/73 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); G01N 2333/705 (2013.01); G01N 2800/52 (2013.01)] 22 Claims
 
1. A method for treating a cancer patient having a cancer characterized by cancer cells expressing CLDN6 on the cell surface, said method comprising:
administering to the patient (i) an anti-CLDN6 antibody and (ii) an agent of chemotherapy, wherein the antibody comprises (a) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 5 or a variant thereof wherein said variant comprises complementarity determining regions CDR1, CDR2, and CDR3 that are identical to complementarity determining regions of SEQ ID NO: 5 and said variant of SEQ ID NO: 5 has at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 5 and (b) a light chain variable region (VL) comprising (b1) the amino acid sequence of SEQ ID NO: 4 or a variant thereof wherein said variant comprises complementarity determining regions CDR1, CDR2, and CDR3 that are identical to complementarity determining regions of SEQ ID NO: 4 and said variant of SEQ ID NO: 4 has at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 4 or (b2) the amino acid sequence of SEQ ID NO: 12 or a variant thereof wherein said variant comprises complementarity determining regions CDR1, CDR2, and CDR3 that are identical to complementarity determining regions of SEQ ID NO: 12 and said variant of SEQ ID NO: 12 has at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 12, and
wherein the agent of chemotherapy comprises a multi-chemotherapy comprising cisplatin, etoposide and bleomycin (PEB).